Patent · US Active

HBV vaccines and methods treating HBV

US11497808B2 · kind B2 · utility

2Cited by

40References

19Claims

0Family size

Assignee

Gilead Sciences, Inc. · US

Inventors

Scott J. Balsitis · Moss Beach, US
Sarah M. Ahmadi-Erber · Wien, AT
Timo Schippers · Wien, AT
Sarah Schmidt · Frankfurt, DE

Key dates

Filing date	Sep 28, 2020
Grant date	Nov 15, 2022
Priority date	—
Expiry date	Sep 28, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are HBV immunogenic polypeptides, polynucleotides encoding such polypeptides, vectors expressing such immunogenic polypeptides for use in eliciting an immune response against HBV; pharmaceutical and immunogenic compositions and kits comprising such polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HBV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.